Anthropic Partners With Biotech Firms to Accelerate Drug Discovery

Anthropic partnered with six organizations, including Bristol Myers Squibb, Generate Biomedicines, and BigHat Biosciences, to accelerate the discovery of drugs for cancer, food allergies, and rare diseases. While most projects remain in the preclinical stage, the collaborations have already produced significant technical results.

Generate Biomedicines used AI to redesign CAR T-cell therapy for solid tumors, resulting in 10 times more receptors. BigHat Biosciences developed a drug candidate that bound to its target 10 times more tightly than the original version. In other collaborations, Divergence Labs generated 35,000 antibody designs for food allergies within a single month, and Enveda reduced the time required for manufacturing document reviews by 89%.

Beyond these partnerships, the company is conducting internal research into rare childhood muscular dystrophy. Anthropic expects one candidate from this research to potentially enter human clinical trials by late 2028.